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Abstract
Background
Hemodialysis (HD) patients have a high risk of infections. The uremic milieu has a negative
impact on several immune responses. Online hemodiafiltration (HDF) may reduce the risk
of infections by ameliorating the uremic milieu through enhanced clearance of middle mole-
cules. Since there are few data on infectious outcomes in HDF, we compared the effects of
HDF with low-flux HD on the incidence and type of infections.
Patients and Methods
We used data of the 714 HD patients (age 64 ±14, 62%men, 25% Diabetes Mellitus, 7%
catheters) participating in the CONvective TRAnsport STudy (CONTRAST), a randomized
controlled trial evaluating the effect of HDF as compared to low-flux HD. The events were
adjudicated by an independent event committee. The risk of infectious events was com-
pared with Cox regression for repeated events and Cox proportional hazard models. The
distributions of types of infection were compared between the groups.
Results
Thirty one percent of the patients suffered from one or more infections leading to hospitaliza-
tion during the study (median follow-up 1.96 years). The risk for infections during the entire
follow-up did not differ significantly between treatment arms (HDF 198 and HD 169 infections
in 800 and 798 person-years respectively, hazard ratio HDF vs. HD 1.09 (0.88–1.34), P =
0.42. No difference was found in the occurrence of the first infectious event (either fatal, non-
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fatal or type specific). Of all infections, respiratory infections (25% in HDF, 28% in HD) were
most common, followed by skin/musculoskeletal infections (21% in HDF, 13% in HD).
Conclusions
HDF as compared to HD did not result in a reduced risk of infections, larger studies are
needed to confirm our findings.
Trial Registration
ClinicalTrials.gov NCT00205556
Introduction
Infections are an important cause for morbidity and mortality in hemodialysis (HD) patients
[1]. The uremic environment affects both the innate and the adaptive immune response by dys-
function of neutrophilic polymorphonuclear leukocytes [2] and monocytes, a depletion of den-
dritic cells, naïve and central memory T cells and B cells [3]. In addition, frequent damaging of
the skin in case of a graft or arterio-venous fistula or the presence of a central venous catheter
facilitates the entry of micro-organisms into the body. Patients with a catheter as a vascular
access have the largest infectious risk, followed by patients with grafts [4–6]. Several patient
related factors contribute to the susceptibility to infection, including older age, hypo-albumine-
mia, co-morbidity, personal hygiene and underlying chronic infectious disease [5,7,8].
Theoretically, amelioration of the uremic milieu by improving clearance of middle mole-
cules by convection might reduce this risk of infections. The HEMO study however, comparing
low-flux with high-flux HD, did not show a decrease in the risk of infections for patients
treated with high flux membranes [5]. Online hemodiafiltration (HDF), a therapy that achieves
markedly better clearance of middle molecules than high-flux HD, might reduce the incidence
of infections. However, removal of middle molecules might also lead to a depletion of immune
effector molecules, pro-inflammatory cytokines, or other mediators relevant for immune func-
tion. In addition, despite tight monitoring and quality control, the infusion of large amounts of
substitution fluid, when contaminated, might impose a larger risk for infections. So far the
effect of HDF on the incidence of infectious episodes as compared to low-flux HD has hardly
been studied. Therefore, we performed a secondary analysis of data of the CONvective TRAns-
port STudy (CONTRAST) to evaluate the effect of HDF as compared to low-flux HD on the
incidence and causes of infection related hospitalizations and mortality.
Methods
General methods
The CONvective TRAnsport STudy (CONTRAST) (ISRCTN38365125, NCT00205556) is a
randomized controlled trial, conducted in twenty-nine dialysis centers in The Netherlands
(n = 26), Canada (n = 2), and Norway (n = 1), that compared the effects of low-flux HD and
online post-dilution HDF on all-cause mortality and cardiovascular morbidity and mortality
[9,10]. Patients were eligible if treated with HD 2 or 3 times a week, for at least 2 months, with
a single pool Kt/Vurea 1.2. Exclusion criteria were age< 18 years, treatment by HDF or high-
flux HD in the 6 months preceding randomization, severe incompliance defined as non-adher-
ence to the dialysis prescription, a life expectancy< 3 months due to causes other than kidney
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disease, and participation in another clinical intervention study evaluating cardiovascular out-
come. All patients were randomized centrally by a computer-based randomization service
(Julius Center University Medical Center, Utrecht, The Netherlands) into a 1:1 ratio for treat-
ment with online hemodiafiltration or continuation of low-flux hemodialysis, stratified per
participating center (permuted blocks). Because of the nature of the intervention, it was not
possible to blind the patients, the local study nurses, or the investigators to the treatment
assignment. The laboratory samples were measured in routine clinical care; hence, personnel
were unaware of treatment assignment. The event adjudication committee was blinded to the
treatment assignment. Patients were enrolled from June 2004 until January 1st 2010 by
nephrologists and research nurses in participating centers. Follow-up ended December 31st
2010. The study was conducted in accordance with the Declaration of Helsinki and centrally
approved by the Medical Ethical committee VU University medical Center, Amsterdam, The
Netherlands, for all the participating hospitals on the 31st of July 2003, an amendment was
approved on 28th of June 2007. Local approval was obtained from the Medical Ethical Commit-
tees of all participating centers, which are listed in the acknowledgements. The authors confirm
that all ongoing and related trials for this intervention are registered. Written informed consent
was obtained from all patients prior to randomization. The study was registrated in the trial
registries after the first patients were enrolled, immediately by the time the investigators knew
trial registration was obligatory. The assessment of difference in risk of infections between dial-
ysis modalities was one of the predefined secondary outcomes [10].
Dialysis procedures
Treatment times were fixed during follow-up in both treatment arms, unless single pool Kt/
Vurea was below 1.2. Online HDF was performed in the post-dilution mode; target volume was
6 L/h. For HDF, synthetic high-flux dialyzers were used (FX80: 24%, FX100: 12% and Optiflux
F200NR: 9% [Fresenius Medical Care, Bad Homburg, Germany]; Polyflux 170H: 20% and
Polyflux 210H: 30% [Gambro AB, Lund, Sweden] or other dialyzers: 4%, based on data of 3
month visit). HD patients were treated with synthetic low-flux dialyzers (F6HPS: 4%, F8HPS:
46% and Optiflux 18NR: 11% [Fresenius]; Polyflux 14L: 4%, Polyflux 17L: 25% and Polyflux
21L: 4% [Gambro], or other: 6%, based on data of 3 month visit). All patients were treated with
ultra pure dialysis fluids, defined as less than 0.1 colony forming units per mL and less than
0.03 endotoxin units per mL. Routine patient care was performed according to national and
international Quality of Care Guidelines.
Data collection
At baseline standardized forms were used to collect demographical, clinical and laboratory
data. Type of vascular access, duration of dialysis (dialysis vintage), and medical history (pres-
ence of diabetes mellitus (DM) and previous cardiovascular disease (CVD)), were also
recorded. CVD was defined as a history of angina pectoris, myocardial infarction, prior coro-
nary revascularization, stroke or transient ischemic attack and/or peripheral vascular disease.
Dialysis vintage was determined as the sum of time patients were treated with HD or peritoneal
dialysis (PD) before inclusion in CONTRAST.
At each three monthly visit, data on clinical events (including infections), dialysis treatment,
medication, and laboratory values were recorded. Infectious events were registered for all
patients before drop out due to transplantation, switch to PD, move to another clinic or stop
for other reasons. All infectious events were adjudicated by an independent Endpoint Adjudi-
cation Committee, whose members reviewed source documentation and were not aware of the
treatment assignments. Infections were adjudicated as categorized definite or probable when
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patients were admitted to the hospital with a clinical picture of an infection, and with labora-
tory results suggesting an infection (leukocytosis, elevated CRP) or when infection was proven
by culture. Infections were also adjudicated when these occurred during an admission for
another cause. Only definite and probable infections were used for this analysis, possible infec-
tions (when a patient was admitted with only a clinical picture of infection, but without ele-
vated inflammation parameters or a positive culture result) were considered as no infections. A
report of two or more infections within a timeframe of 14 days was counted as one infection. If
the second infection was fatal, that infection was used in the analysis. Infections were grouped
as graft or fistula infection, catheter sepsis, sepsis, respiratory, urinary and ‘other infections’.
Those that were categorized as ‘other infection’ have been subdivided into gastro-intestinal,
skin/musculoskeletal, cardiac and miscellaneous infections retrospectively. Written diagnoses
from the adjudication committee were used for this categorization.
In HDF patients, infusion volumes (liters per treatment) were reported as the mean value of
three consecutive treatment sessions. Convection volumes (liters per treatment) were calcu-
lated by the sum of the intradialytic weight loss and the substitution volume. Patients with a
urinary production of less than 100 mL per day were considered anuric.
Routine laboratory values were measured in the different participating hospitals using stan-
dard techniques.
Outcome
The primary study outcome was the risk of hospitalizations due to infection during the follow-
up period. The secondary outcomes were mortality due to an infectious cause, the risk for the
1st fatal or non-fatal infection and the risk for 1st cause specific infection. Furthermore we stud-
ied the distribution of cause specific infections on the event level (enabling the analysis of more
than one infectious event per patient).
All infectious events that occurred after randomisation up to censoring were used in our
analyses. Censoring could be due to death, due to end of study or due to dropping out. Drop-
ping out means that a participant either stopped because of a renal transplantation (n = 151),
switch to PD (n = 11), transfer to another hospital which did not participate in CONTRAST
(n = 24) or due to other reasons (n = 53).
Data analysis
Data were reported as means with standard deviations, medians with interquartile (IQR)
ranges, or proportions when appropriate.
The difference in risk for hospitalization due to infections between patients treated with HDF
and HD during the follow-up was evaluated with a Cox proportional hazards model for repeated
events, which is a Prentice-Williams-Peterson (PWP) conditional model [11]. In this model
patients have a number of follow-up periods, depending on the number of events. The model
takes intra-patient risk for infections into account. Furthermore we added interaction-terms to
this model to explore whether the difference in risk between HDF and HD treated patients was
different for certain predefined subgroups, notable age, sex, presence of CVD, presence of DM,
presence of RKF and dialysis vintage. Furthermore, we explored whether the risk of infections
was affected by the magnitude of the delivered convection volumes during the trial, with using
the HD group as a reference group. In this last model adjustments were made for determinants
of convection volume and mortality. Finally, since the distribution of vascular access type was
somewhat different between patients from the Netherlands and Canada, we evaluated if there
was an interaction between the treatment and the country of residence and performed additional
analyses on these countries separately, with an adjustment for vascular access type.
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The difference in risk for 1st infectious events (fatal- and nonfatal and cause specific infec-
tions) between HDF and HD was analyzed with Cox proportional hazard models. The distribu-
tion of infectious events from different causes was compared on the event level. The analyses
were conducted in SPSS software (version 18.0; SPSS Inc. Headquarters, Chicago, Illinois, US)
and in R (version 2.9.2; 2009 The R Foundation for Statistical Computing).
Results
Patient characteristics at baseline are shown in Table 1. The participant flow chart is shown in
Fig 1. Thirty one percent of the patients suffered from one or more infections leading to hospi-
talization during the study (median follow-up 1.96 years). The treatment effect on risk of infec-
tious events is depicted in Table 2. HDF did not reduce the risk of infections: hazard ratio (HR)
HDF versus HD 1.09 (0.88–1.34), P = 0.42. In addition, no statistically significant differences
were found between the two treatment arms for the first occurring infection (Table 2).
No difference in the effect of HDF was found in subgroups of age (below or above the
median of 67 yrs, P value for the interaction term = 0.44), sex (P = 0.49), DM (present/absent,
P = 0.64), previous CVD (P = 0.14), RKF (present/absent, P = 0.42) and dialysis vintage (below
or above the median of 2 yrs, P = 0.20), or country of residence (P value for the interaction term
= 0.15). We found a trend towards a different effect of HDF in patients with high or low serum
albumin levels (P for interaction = 0.05). The HR (HDF vs. HD) for infections was 1.31 (0.96–
1.79, P = 0.09) in patients with a baseline serum albumin above 40.5 g/L (median), and was
0.86 (0.65–1.13, P = 0.29) in patients with a baseline serum albumin below the median.
Compared to HD, the incidence of infections did not differ across tertiles of convection.
Lowest convection volume tertile HR 1.10 (0.84–1.45), P = 0.49, middle convection tertile HR
1.13 (0.85–1.50), P = 0.41, highest convection tertile HR 0.88 (0.64–1.20), P = 0.42 (all versus
HD and adjusted for country of origin). This result remained unaltered after adjustment for
age, sex, CVD, DM, hematocrit, serum albumin, treatment time, blood flow rate, vascular
access and site.
Of all infections, respiratory infections (25% in HDF, 28% in HD) were most common, fol-
lowed by skin/musculoskeletal infections (21% in HDF, 13% in HD) (Tables 3 and 4).
Table 5 shows that the distribution of access types was different between patients treated in
the Netherlands and in Canada. The risk for infections was neither changed by HDF in the
Netherlands (HR 1.15 (0.91–1.45, P = 0.23) nor in Canada (HR 0.93 (0.55–1.56, P = 0.79).
Since the proportion of patients treated with grafts in the Netherlands was larger in the HDF
group, we adjusted for access type at baseline. The HR’s for the Netherlands and for Canada
remained however comparable (1.13 (0.90–1.43, P = 0.29) and 0.93 (0.55–1.56, P = 0.78)
respectively.
Discussion
In this large randomized controlled trial we found that 31% of the participants suffered from
one or more infections leading to hospitalization during the study (median follow-up 1.96
years). Our results suggest that treatment with HDF does not reduce the risk of mortality and
hospitalization due to infections as compared to HD. The most common infections in both
treatment arms were respiratory infections and skin/musculoskeletal infections.
To our knowledge, this is the first study investigating the risk of infections in patients
treated with HDF as compared to patients treated with low-flux HD. Our data indicate that
alteration of the uremic milieu by convective clearance does not reduce the risk of infections.
Our data are in line with the results of the HEMO study, which showed that high flux HD did
not decrease the risk of infectious outcomes [5]. Also in the Turkish HDF study no difference
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in infectious related mortality was found between HDF and high-flux HD patients[12]. How-
ever, they only reported mortality from infections[12]. Our results are different from the results
of the Spanish ESHOL study in which a reduced mortality by infections was found in the online
HDF group as compared to the high-flux HD group[13]. However, they neither showed a dif-
ference in the number of infectious related hospitalizations between patients treated with HDF
and HD. They did not report categories of infection[13].
Table 1. Baseline characteristics of the patients.
Variable HDF(n = 358) HD(n = 356)
Age (year) 64.1±14.0 64.0±13.4
Male sex—no. (%) 214 (60) 231 (65)
Region
Netherlands-no. (%) 300 (84) 297 (83)
Canada- no. (%) 51 (14) 51(14)
Norway- no. (%) 7 (2) 8 (2)
History of cardiovascular disease—no. (%) 151 (42) 162 (46)
Diabetes mellitus—no. (%) 92 (26) 78 (22)
Body mass index after dialysis—kg/m2 25.2±5.0 25.6±4.6
Dialysis vintage (year)
-Median (inter-quartile range) 1.8 (1.0–3.7) 2.1 (1.0–4.0)
Systolic blood pressure—mmHg 147±21 148±22
Diastolic blood pressure-mmHg 75±12 76±12
Vascular access
Arteriovenous ﬁstula- no. (%) 279 (78) 288 (81)
Graft- no. (%) 57 (16) 43 (12)
Central catheter- no. (%) 22 (6) 25 (7)
Number of treatments/week
-3- no. (%) 332 (93) 338 (95)
-2- no. (%) 26 (7) 18 (5)
Duration of a dialysis session—min 226±26 227±22
Blood ﬂow—mL/min 302±39 299±41
Dialysis single pool Kt/Vurea 1.41±0.24. 1.38±0.19
Residual kidney function no.(%)* 186 (52) 190 (53)
Estimated glomerular ﬁltration rate
-ml/min/1.73m2; median (inter-quartile range) 0.32 (0–3.30) 0.30 (0–3.35)
Hemoglobin—mmol/L 7.4±0.82 7.3±0.73
Phosphorus—mmol/L 1.65±0.51 1.63±0.47
Beta-2-microglobulin—mg/L 30.7±14.3 32.3±13.6
Albumin—g/L^ 40.2±3.8 40.6±3.9
Creatinine–μmol/L pre-dialysis 842±260 879±250
Values are means ±SD, median (interquartile range) or number (percentage).
HDF = online hemodiaﬁltration; HD = hemodialysis;
~pre-dialysis
*residual kidney function if diuresis >100 ml/24h
^albumin concentrations measured with the bromcresolpurple method have been converted to the
bromcresolgreen method
To convert hemoglobin in mmol/L to g/dL divide by 0.62; phosphorus in mmol/L to mg/dL, divide by 0.323;
albumin in g/L to g/dL, divide by 10; creatinine in μmol/L to mg/dL divide by 88.4
doi:10.1371/journal.pone.0135908.t001
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In our study we found a trend towards a higher risk of sepsis in HDF patients. However, it
may be a chance finding, since the number of patients in whom a sepsis or catheter sepsis
occurred was small. Also, if we would take multiple testing into account, the association would
be far from statistically significant. We do not have a theoretical explanation for the trend
towards an increased number of sepsis in the HDF group. We neither have an explanation for
a potentially different effect of HDF in patients with an albumin below or above the median,
this might be a chance finding as well.
The impact of various dialysis modalities on immune function is speculative. There is no
evidence that alteration of dialysis efficiency or improving clearance of middle molecules from
the blood would have a beneficial effect on immune processes on the tissue level. HDF might
enhance the clearance of deleterious molecules such as complement factor D, granulocyte
inhibitory protein II (GIP II) and immunoglobulin free light chains, which have been shown to
have an in vitro depressant effect on degranulation, chemotaxis and phagocytosis of mainly
polymorphonuclear leukocytes [14]. Alternatively, HDF may also enhance the clearance of
immune-active molecules such as cytokines, or other unknown molecules essential for immune
function. The limited data on clearance of specific toxins by HDF and the in vitro and in vivo
function of these toxins makes it very difficult to explain clinical outcomes. In addition, despite
tight monitoring and quality control, the infusion of large amounts of substitution fluid, when
contaminated, might impose a larger risk for infections. However we showed in a previous
study that microbiological cultures of the substitution fluid were negative in 98% of 193 tested
samples and endotoxin levels were below the reference quality level in 98% of 177 tested sam-
ples [15].
The groups of respiratory infections (25–28%) and skin/musculoskeletal infections (13–
21%) were the most common infections in our study. These infections occurred more often in
Fig 1. Enrolment, randomization, and follow-up of study participants. For infections, all patients were followed until drop out, death or the end of the
study.
doi:10.1371/journal.pone.0135908.g001
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the same patients as well. In the HEMO study the contribution of respiratory disease as the
cause for an infection related hospitalization was 22% as well [5]. Infections from cardiac,
peripheral vascular disease, DM, hepatobiliary disease, musculoskeletal and gastrointestinal
causes, which were included in our category ‘other infections’, also contributed to 31% of infec-
tion related hospitalizations [5]. The contribution of septicaemia and bacteremia and infections
due to vascular access complications was larger than in our study, despite a comparable use of
catheters in only 8% of patients [5]. Considering respiratory infections, a study from the United
States (US) retrospectively linked Medicare claims to Dialysis Morbidity and Mortality Study
data sets and reported that over an average follow-up of 3.3 years 28.9% of the study population
was hospitalized with a pneumonia [16], which was 11% in a median follow-up of 1.96 years in
our study. Another study from the US also based on claim data of Medicare reported a septi-
caemia rate of 17.5 per 100 patient years in HD patients in 1999, which is probably due to a
high use of catheters [17]. The risk of non vascular access related infections, septicaemia related
hospitalizations and infections of vascular access reported from an analysis of 5 European
DOPPS countries was comparable to our study [18]. It remains however difficult to compare
studies from different continents and data that are collected retrospectively or prospectively.
The strengths of our study are the randomized design and the prospective collection of the
data on infectious events, including the categories of infection. Furthermore, all infectious
events were adjudicated and all infections during the on treatment follow-up were taken into
account in the data-analyses. A limitation is the fact that this study was powered on mortality
Table 2. The risk for infectious events in patients treated with HD and HDF
HDF (n = 358) HD (n = 356)
Event No. of events Person-years of FU No. of events Person-years of FU HR HDF vs HD (95%CI) P
All infections 198 800 169 798 1.09 ¶ 0.42
(0.88–1.34)
Fatal infection* 23 800 28 798 0.85 ^ 0.56
(0.49–1.47)
1st Graft- or ﬁstula infection 11 787 11 788 0.99 ^ 0.98
(0.43–2.29)
1st Catheter sepsis 14 787 8 781 1.77 ^ 0.20
(0.74–4.22)
1st Sepsis 17 790 7 794 2.40 ^ 0.05
(1.00–5.79)
1st Urinary tract infection 10 792 12 781 0.82 ^ 0.64
(0.35–1.89)
1st Respiratory infection 37 744 38 756 0.98 ^ 0.98
(0.62–1.53)
1st Other infection 52 735 38 755 1.40 ^ 0.11
(0.92–2.13)
1st non-fatal or fatal infection 118 652 106 681 1.16 ^ 0.27
(0.89–1.51)
HDF = Online hemodiaﬁltration; HD = Low-ﬂux hemodialysis; No. = number; FU = follow-up; HR = hazard ratio
¶ analyzed with Cox for repeated events
^obtained through unadjusted Cox proportional hazards models, time to (ﬁrst) infectious event
*On treatment analysis, so infectious death on treatment of HD or HDF or within 28 days after censoring due to transplantation, switch to PD, move to
other clinical or stop for other reasons
doi:10.1371/journal.pone.0135908.t002
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and not on infections, so the study is underpowered to detect smaller, clinically relevant, differ-
ences. So a beneficial or harmful effect of treatment with HDF cannot be ruled out completely
based on our findings. As the 95% of the HR (1.09) was 0.88–1.34, the effect of online HDF
may vary between a 12% reduction and a 34% increase in hospitalization for infections, both
extremes being clinically relevant. Most important in this superiority trial, a small beneficial
effect for HDF can still exist. Furthermore the lack of cause specific registration of fatal infec-
tions, the retrospective categorization of the category ‘other infections’ and the generalizability
to non-European countries, with a different composition of vascular accesses might be
limitations.
More and larger studies are needed to confirm our findings. These studies should be pow-
ered on the incidence on infections, to rule out that the lack of effect we found, is not due to a
Table 3. Total number of infectious events by cause
HDF HD
Event Total no. of events In n patients % of all infections Total no. of events In n patients % of all infections
(95% CI) (95% CI)
Fatal infection* 23 23 11.6 28 28 16.6
(7.1–16.1) (11.0–22.2)
Graft- or ﬁstula infection 11 11 5.6 12 11 7.1
(2.4–8.7) (3.2–11.0)
Catheter sepsis 16 14 8.1 8 8 4.7
(4.3–11.9) (1.5–7.9)
Sepsis 18 17 9.1 7 7 4.1
(5.1–13.1) (1.1–7.1)
Urinary tract infection 12 10 6.1 15 12 8.9
(2.7–9.4) (4.6–13.2)
Respiratory infection 49 37 24.7 47 38 27.8
(18.7–30.8) (21.1–34.6)
Other infection 69 52 34.8 52 38 30.8
(28.2–41.5) (23.8–37.7)
Total no. of infections 198 118 100 169 106 100
HDF = Online hemodiaﬁltration; HD = Low-ﬂux hemodialysis; no. = number
*On treatment analysis, so infectious death on treatment of HD or HDF or within 28 days after censoring due to transplantation, switch to PD, move to
other clinic or stop for other reasons
Note: one patient may have more than one infectious event
doi:10.1371/journal.pone.0135908.t003
Table 4. Distribution of other infections in online hemodiafiltration and hemodialysis
HDF HD
No. % of all infections No. % of all infections
Gastro-intestinal 17 8.6 (4.7–12.5) 13 7.7 (3.7–11.7)
Skin/musculoskeletal 42 21.2 (15.5–26.9) 22 13.0 (7.9–18.1)
Cardiac 2 1.0 (0–2.4) 1 0.6 (0–1.7)
Miscellaneous 8 4.0 (1.3–6.8) 16 9.5 (5.1–13.9)
Total 69 52
HDF = online hemodiaﬁltration; HD = hemodialysis; No. number
doi:10.1371/journal.pone.0135908.t004
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lack of power. These studies should be designed as inferiority trials, to explore the trend
towards more sepsis in the HDF group. The FINESSE trial, comparing high-flux HD with
HDF, will investigate episodes of septicaemia as a secondary safety outcome [19]. Furthermore,
data from the HDF Pooling Project could confirm our findings [20].
In conclusion, as compared to HD, our data suggest that treatment with HDF does not
reduce the risk of infectious episodes in patients with end stage renal disease.
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